Amgen Inc

[admin]

Participez aux échanges de la file de discussion concernant

Amgen Inc

[pleclech]

Amgen plus haut historique

Bonjour,

la valeur Amgen possède vraiment un profil intéressant. De nouveaux plus hauts et un gap ENORME au départ du mouvement haussier. Cette action à beaucoup pour plaire à moyen et long terme. Un beau profil
https://<a href='/ref.php?uri=http%3...ttgann.com</a>

[polaille]

Salut,
c'est clair, et avant ce gap, une des plus belle rupture de volat de l'année, avec une prpagation du mouvement aux unités weekly et monthly.

[polaille]

AMGEN & ABGENIX, Cancer therapy slows tumor growth

citation :

---

By Steve Johnson
Mercury News

Southern California biotech giant Amgen and small biotech Abgenix of Fremont announced Thursday that their colon cancer drug panitumumab slowed tumor growth, almost cutting in half the chance the cancer would worsen.

In a test involving 463 people with advanced colon cancer, those given panitumumab showed a 46 percent decrease in tumor progression. That exceeded the original goal of a 33 percent decrease, the companies said.

``We're very pleased,'' said Gisela Schwab, Abgenix's chief medical officer. ``I think this is an important study showing if this moves forward in the marketplace, we have another compound that can hopefully help.''

The test was done in patients who showed no benefit from other chemotherapy. Of the 463 in the study, 231 were given panitumumab.

Schwab said the companies would seek approval next year from the U.S. Food and Drug Administration to begin selling the drug. It would be Abgenix's first commercial product.

CIBC World Markets, a Wall Street analysis firm that tracks Amgen and Abgenix, also was impressed. It issued a report Thursday that said ``panitumumab should be a very tough competitor'' for Erbitux, a colon cancer drug marketed by Bristol-Myers-Squibb and ImClone Systems.

One cancer specialist said panitumumab's results seemed ``impressive'' but it's too soon to know how it compares with other recent colon-cancer drugs like Avastin. ``I think it will add to the number of arrows that we have in our quiver, so to speak, to fight colon cancer,'' said Dr. Richard Adrouny of Los Gatos, who has written a book about colon cancer.

Developed jointly by Amgen and Abgenix, panitumumab is an antibody that targets a substance that can stimulate cancer cells to grow, called epidermal growth factor receptor, or EGFr. Panitumumab attaches to the EGFr, interfering with the process that tends to stimulate cancer cells to grow.

Colorectal cancer is the third most common form of cancer diagnosed in the United States, according to the American Cancer Society. It estimates that nearly 105,000 new cases of colon cancer will be diagnosed this year.

Thursday's announcement sent Abgenix's stock soaring to $3.53 a share, up 38 percent, to equal its 52-week high of $12.90 at the close of trading on the Nasdaq Stock Market. Amgen, based in Thousand Oaks, saw its stock close up $3.61 a share, or 5 percent, to $77.51 in trading on the Nasdaq.

---

Amgen pourrait à la suite de cette nouvelle enclencher un nouveau mouvement haussier, avec un premier objectif à -85.30- à court terme.
Amgen a formé un support daily à -73.40-, suivi d'une rupture de volatilité.



Abgenix suit le mouvement, avec une hausse de 38% et l'ouverture d'un important gap.
La feinte de corps sous -9.20- à la veille de l'annonce a du en surprendre plus d'un.
L'attaque a perforé la résistance, ont peut envisager une consolidation à court terme en direction des -11- (support weekly).

[polaille]

citation :

---

Amgen to acquire Abgenix for about $2.2 billion
Wed Dec 14, 2005 4:33 PM ET

LOS ANGELES, Dec 14 (Reuters) - Amgen Inc. (AMGN.O: Quote, Profile, Research), the world's largest biotechnology company, said on Wednesday that it plans to acquire Abgenix Inc. (ABGX.O: Quote, Profile, Research) for about $2.2 billion in cash, giving it full control over the cancer drug the two are developing.

Amgen said it expects the deal to reduce its adjusted earnings per share in 2006 and 2007 by 5 cents to 10 cents, and to add to earnings thereafter, assuming commercial success of experimental cancer drug panitumumab.

Amgen, headquarter in Thousand Oaks, California, said it will pay $22.50 a share for Fremont, California-based Abgenix, plus assumption of debt.

"Abgenix is a natural strategic fit for Amgen given our strong existing relationship. ... This investment reflects Amgen's commitment to our pipeline and our growing confidence in the future success of both panitumumab and denosumab," Kevin Sharer, Amgen's president and chief executive officer, said in a statement.

The companies announced last month that panitumumab was shown to slow tumor growth in patients with advanced colon cancer who did not respond to chemotherapy.

Amgen said it believes that potential peak worldwide sales for the drug could reach $2 billion or more.

Denosumab, another antibody-based drug, is being developed as a treatment for osteoporosis.

The deal, still subject to the approvals of Abgenix's shareholders and regulatory authorities, and to other customary closing conditions, is expected to close by the end of the first quarter of 2006.

Shares of Abgenix, which closed at $14.65 on Nasdaq, were not trading after hours, while shares of Amgen, which closed at $76.78, were higher at $78.10 in after-hours trading.

---

S'il n'y a plus grand chose à ajouter sur Abgenix, la config d'Amgen est intéressante, avec le comblement du gap haussier daily. Voila qui devrait repartir vers les -84.50- puis -86.90-.

[polaille]

Amgen a coupé court au support formé par le gap haussier.

Le support weekly est légèrement plus bas.

[polaille]

AMGN est en route pour le support weekly à 73.50

[Mohamed ALAMI]

AMGEN : Target $ 72.70 ?




SL sous les plus bas récents.

[Mohamed ALAMI]

Cibles Intermédiaires :
68. 98 - 69.90 - 70.83 - 72.14